

# **Ketorolac tromethamine injection Recall Alert**

Date of Notice: 03/04/2020

## **Brief Description of Recall**

On March 4, 2020, Hikma Pharmaceuticals USA, Inc. extended its previously announced recall of ketorolac tromethamine injection due to the presence of small visible particulate matters of a gelatinous/oily nature.

Administration of the affected drug could potentially result in the deposition of particulates in the lungs of patients, which could result in multiple pulmonary microemboli with subsequent acute respiratory distress for patients receiving the drug intravenously.

## **Affected Products**

Drug Name & Strength	NDC	Lot	<b>Expiration Date</b>
Ketorolac Tromethamine Injection 30mg/mL	0641-6042-25	038366	03/2020
		048365 048367	04/2020
		078301 078303	07/2020
		118358	11/2020
		019413	01/2021
		029353	02/2021

### **Prescriber Information**

Hikma has not received any reports of adverse events related to this issue.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report Online
- Regular Mail or Fax: <u>Download form</u> or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

## **Member Information**

Members should contact their doctor if they have experienced any problems that may be related to taking or using this drug product.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

<sup>© 2020</sup> RxAdvance Corporation. Confidential and Proprietary.



For recall inquiries, please contact Hikma using the information provided below:

Contact	Contact Information	Support
Hikma Pharmaceuticals USA Inc. – Customer Service	(P): (800) 631-2174 (E): usrecall@hikma.com (F): (732) 542-0940 Hours of operation, M-F: 8:00am-7pm (EST)	Recall related inquires
Qualanex LLC (Hikma 3rd Party Recall Service Provider)	Qualanex LLC 1410 Harris Road Libertyville, IL 60048-2435 (E): recall@qualanex.com	Product Returns

**RxAdvance Response** 

RxAdvance is in the process of contacting members and prescribers to advise them of this recall.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© 2020 RxAdvance Corporation. Confidential and Proprietary.